STEM CELL THERAPY FOR DIABETES
Background: Diabetes is a condition which is proposed to affect upwards of 2/3 + of the US population by the year 2020 imposing an extreme economic burden on the healthcare system.
Diabetes market:
Ø Diabetes affects 285 million people worldwide.
Ø 7 million people develop diabetes each year
Ø This number is expected to hit 438 million by 2030
Ø The incidence is increasing due to the aging population, increasing rates of obesity and sedentary lifestyle
Ø Considerable costs for healthcare system and loss of work
Ø People with diabetes incur medical costs that are two to three times higher than those without diabetes. A person with diabetes can face direct costs for medication and supplies ranging from $1,000 to $15,000 a year.
Ø By 2020, it’s estimated that diabetes will cost select healthcare system $16.9 billion a year.
Discovery data: Although there have been reports on stem cell therapy for diabetes – these have been predominantly from embryonic stem cells sources which have had limited success by being (a) seen as foreign and thus rejected by the recipients body and (b) having risks of malignancy.
We have applied a revolutionary approach to mature blood derived stem cells for the application to diabetes. The benefit of this approach is that the blood derived stem cells are taken from the patients own body and as such would be recognized as self and therefore not rejected. In addition these cells are not immortalized the same way as embryonic stem cells and therefore do not pose the same risks for malignancy. We have laid the groundwork to grow new pancreas islet cells (the cells that make insulin) for use in clinical trials.
IP: the technology has not been fully disclosed and is secure for subsequent proprietization.
REFERENCES
Bluth MH, Viterbo D, Lin YY, Mueller CM, Smith-Norowitz T, Zenilman ME. (2005)
Pancreatitic serum induces morphological changes in macrophages. Pancreas 31, 434.
Bluth MH, Meeus S, Chapman M, Pierre J, Mueller C, Stanek A, Zenilman M.
(2006)”Blood Monocytes Maintain Stem Cell Plasticity after Repeated Growth Factor
Challenge” FASEB Journal 20, A1106.
Chapman M, Bluth MH. Characterization of Blood Derived Stem Cells. Ethnicity and
Disease 2007, 17; S5-7
Bluth MH. Stem cells in medicine: Applications and concerns. International Journal of Medical Implants and Devices 2007;2:27-28.
Background: Diabetes is a condition which is proposed to affect upwards of 2/3 + of the US population by the year 2020 imposing an extreme economic burden on the healthcare system.
Diabetes market:
Ø Diabetes affects 285 million people worldwide.
Ø 7 million people develop diabetes each year
Ø This number is expected to hit 438 million by 2030
Ø The incidence is increasing due to the aging population, increasing rates of obesity and sedentary lifestyle
Ø Considerable costs for healthcare system and loss of work
Ø People with diabetes incur medical costs that are two to three times higher than those without diabetes. A person with diabetes can face direct costs for medication and supplies ranging from $1,000 to $15,000 a year.
Ø By 2020, it’s estimated that diabetes will cost select healthcare system $16.9 billion a year.
Discovery data: Although there have been reports on stem cell therapy for diabetes – these have been predominantly from embryonic stem cells sources which have had limited success by being (a) seen as foreign and thus rejected by the recipients body and (b) having risks of malignancy.
We have applied a revolutionary approach to mature blood derived stem cells for the application to diabetes. The benefit of this approach is that the blood derived stem cells are taken from the patients own body and as such would be recognized as self and therefore not rejected. In addition these cells are not immortalized the same way as embryonic stem cells and therefore do not pose the same risks for malignancy. We have laid the groundwork to grow new pancreas islet cells (the cells that make insulin) for use in clinical trials.
IP: the technology has not been fully disclosed and is secure for subsequent proprietization.
REFERENCES
Bluth MH, Viterbo D, Lin YY, Mueller CM, Smith-Norowitz T, Zenilman ME. (2005)
Pancreatitic serum induces morphological changes in macrophages. Pancreas 31, 434.
Bluth MH, Meeus S, Chapman M, Pierre J, Mueller C, Stanek A, Zenilman M.
(2006)”Blood Monocytes Maintain Stem Cell Plasticity after Repeated Growth Factor
Challenge” FASEB Journal 20, A1106.
Chapman M, Bluth MH. Characterization of Blood Derived Stem Cells. Ethnicity and
Disease 2007, 17; S5-7
Bluth MH. Stem cells in medicine: Applications and concerns. International Journal of Medical Implants and Devices 2007;2:27-28.